Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zhaoke Says Novel Dry Eye Treatment Hits Endpoint in Phase III Trial

publication date: Aug 20, 2021

Zhaoke Ophthalmology of Guangzhou said its dry eye disease treatment met the primary endpoint in a China Phase III trial. Cyclosporine A (CsA) Ophthalmic Gel is administered once daily, as opposed to the twice-daily dosing of competing products. CsA is a proprietary hydrogel designed to stay on the cell surface longer, improving efficacy. In the Phase III trial, CsA showed a significant improvement in the inferior fluorescein corneal staining score. Zhaoke, an indirect non-wholly-owned subsidiary of Lee's Pharm, develops Lee's portfolio of in-licensed ophthalmology drugs. More details....

Stock Symbols: (HK: 6622) (HK: 0950)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.